News

Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.

DaVita has outperformed other healthcare stocks over the past year, and analysts remain moderately optimistic about its growth prospects.

HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 22nd, 2026.

Murphy, DaVita, Hewlett Packard and Vishay have been highlighted in this Screen of The Week article.

DaVita HealthCare (DVA) closed the most recent trading day at $207.91, moving 1.27% from the previous trading session.

Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, HPE and VSH are seeing price strength, and the momentum is likely to continue.

DVA is expanding kidney care beyond hospitals with IKC, digital tools and AI to improve coordination, lower costs and support patients.

ECPG, DK and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 17, 2026.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 17, 2026.

One dominates kidney care with global reach, while the other leads in rehab with faster growth and higher margins. Which business model stands out for 2026?

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 15, 2026.

For investors wondering whether DaVita at around US$208.66 is offering fair value or trading at a stretched price, this article walks through what the numbers are really saying about the stock. The stock has returned 8.6% over the past week, 4.5% over the last month, 82.2% year to date and 53.3% over the past year, which has put its recent performance firmly on investors' radar. Recent attention around DaVita has largely centred on its role in the US healthcare sector and on how the market...

Banking giant BMO, Astronics, DaVita and Intercorp Financial make new highs Friday as the stock market aims to rebound.

In the most recent trading session, DaVita HealthCare (DVA) closed at $203.83, indicating a +2.66% shift from the previous trading day.

DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here is how Alignment Healthcare (ALHC) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

PRTH, DVA and BFH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 11, 2026.

DVA, HRB, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 11, 2026.

Encompass Health deepens its Georgia presence with a new rehab hospital as rising demand, expanding capacity and strong operating trends fuel growth.

DVA expands its IKC platform, tops CKCC savings in first-quarter 2026 and rolls out AI ScheduleHub to boost scheduling and staffing.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare are benefiting from telehealth, AI adoption and growing home-care demand.

DaVita (NYSE:DVA) has entered into a Ninth Amendment to its Credit Agreement providing an incremental $500 million senior secured term loan. The company plans to use the proceeds to repay existing debt, cover related transaction costs, and support general corporate purposes. This new term loan represents a material update to DaVita's capital structure and available liquidity. For investors tracking NYSE:DVA, this financing step comes with the stock trading around $198.19 and showing a 73.1%...

An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.

DVA, XPO, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 9, 2026.

THG, DVA and PLOW made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 9, 2026.

FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.

DaVita (DVA) is back in focus after first quarter 2026 revenue and earnings surpassed analysts' expectations, prompting management to lift full year guidance and drawing fresh attention from investors and research desks. See our latest analysis for DaVita. The strong first quarter has come after a powerful run in the stock, with the share price up 27.46% over 90 days and a 67.81% year to date share price return. The 3 year total shareholder return of 97.13% suggests longer term holders have...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at outpatient & specialty care stocks, starting with DaVita (NYSE:DVA).